214 related articles for article (PubMed ID: 34810000)
1. Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework.
Lau CL; Mayfield HJ; Sinclair JE; Brown SJ; Waller M; Enjeti AK; Baird A; Short KR; Mengersen K; Litt J
Vaccine; 2021 Dec; 39(51):7429-7440. PubMed ID: 34810000
[TBL] [Abstract][Full Text] [Related]
2. Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine.
Mayfield HJ; Lau CL; Sinclair JE; Brown SJ; Baird A; Litt J; Vuorinen A; Short KR; Waller M; Mengersen K
Vaccine; 2022 May; 40(22):3072-3084. PubMed ID: 35450781
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
MacIntyre CR; Veness B; Berger D; Hamad N; Bari N
Vaccine; 2021 Aug; 39(34):4784-4787. PubMed ID: 34272095
[TBL] [Abstract][Full Text] [Related]
4. Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
Lane S; Shakir S
Drug Saf; 2022 Sep; 45(9):1003-1008. PubMed ID: 35927605
[TBL] [Abstract][Full Text] [Related]
5. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.
Tran Kiem C; Andronico A; Bosetti P; Paireau J; Alter L; Boëlle PY; Fontanet A; Lévy-Bruhl D; Cauchemez S
Euro Surveill; 2021 Jul; 26(26):. PubMed ID: 34212840
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian network analysis quantifying risks versus benefits of the Pfizer COVID-19 vaccine in Australia.
Sinclair JE; Mayfield HJ; Short KR; Brown SJ; Puranik R; Mengersen K; Litt JCB; Lau CL
NPJ Vaccines; 2022 Aug; 7(1):93. PubMed ID: 35953502
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Sánchez van Kammen M; Aguiar de Sousa D; Poli S; Cordonnier C; Heldner MR; van de Munckhof A; Krzywicka K; van Haaps T; Ciccone A; Middeldorp S; Levi MM; Kremer Hovinga JA; Silvis S; Hiltunen S; Mansour M; Arauz A; Barboza MA; Field TS; Tsivgoulis G; Nagel S; Lindgren E; Tatlisumak T; Jood K; Putaala J; Ferro JM; Arnold M; Coutinho JM; ; Sharma AR; Elkady A; Negro A; Günther A; Gutschalk A; Schönenberger S; Buture A; Murphy S; Paiva Nunes A; Tiede A; Puthuppallil Philip A; Mengel A; Medina A; Hellström Vogel Å; Tawa A; Aujayeb A; Casolla B; Buck B; Zanferrari C; Garcia-Esperon C; Vayne C; Legault C; Pfrepper C; Tracol C; Soriano C; Guisado-Alonso D; Bougon D; Zimatore DS; Michalski D; Blacquiere D; Johansson E; Cuadrado-Godia E; De Maistre E; Carrera E; Vuillier F; Bonneville F; Giammello F; Bode FJ; Zimmerman J; d'Onofrio F; Grillo F; Cotton F; Caparros F; Puy L; Maier F; Gulli G; Frisullo G; Polkinghorne G; Franchineau G; Cangür H; Katzberg H; Sibon I; Baharoglu I; Brar J; Payen JF; Burrow J; Fernandes J; Schouten J; Althaus K; Garambois K; Derex L; Humbertjean L; Lebrato Hernandez L; Kellermair L; Morin Martin M; Petruzzellis M; Cotelli M; Dubois MC; Carvalho M; Wittstock M; Miranda M; Skjelland M; Bandettini di Poggio M; Scholz MJ; Raposo N; Kahnis R; Kruyt N; Huet O; Sharma P; Candelaresi P; Reiner P; Vieira R; Acampora R; Kern R; Leker R; Coutts S; Bal S; Sharma SS; Susen S; Cox T; Geeraerts T; Gattringer T; Bartsch T; Kleinig TJ; Dizonno V; Arslan Y
JAMA Neurol; 2021 Nov; 78(11):1314-1323. PubMed ID: 34581763
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccines and thrombosis with thrombocytopenia syndrome.
Lai CC; Ko WC; Chen CJ; Chen PY; Huang YC; Lee PI; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1027-1035. PubMed ID: 34176415
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the effect of delaying the second COVID-19 vaccine dose in England: a mathematical modelling study.
Imai N; Rawson T; Knock ES; Sonabend R; Elmaci Y; Perez-Guzman PN; Whittles LK; Kanapram DT; Gaythorpe KAM; Hinsley W; Djaafara BA; Wang H; Fraser K; FitzJohn RG; Hogan AB; Doohan P; Ghani AC; Ferguson NM; Baguelin M; Cori A
Lancet Public Health; 2023 Mar; 8(3):e174-e183. PubMed ID: 36774945
[TBL] [Abstract][Full Text] [Related]
10. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis.
Palaiodimou L; Stefanou MI; Katsanos AH; Aguiar de Sousa D; Coutinho JM; Lagiou P; Michopoulos I; Naska A; Giannopoulos S; Vadikolias K; Voumvourakis KI; Papaevangelou V; Vassilakopoulos TI; Tsiodras S; Tsivgoulis G
Neurology; 2021 Nov; 97(21):e2136-e2147. PubMed ID: 34610990
[TBL] [Abstract][Full Text] [Related]
11. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
12. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
[TBL] [Abstract][Full Text] [Related]
13. [Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination].
Kawano H; Hashimoto Y; Hirano T
Rinsho Shinkeigaku; 2021 Sep; 61(9):594-601. PubMed ID: 34373413
[TBL] [Abstract][Full Text] [Related]
14. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.
Ostrowski SR; Søgaard OS; Tolstrup M; Stærke NB; Lundgren J; Østergaard L; Hvas AM
Front Immunol; 2021; 12():779453. PubMed ID: 34887867
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis.
Hafeez MU; Ikram M; Shafiq Z; Sarfraz A; Sarfraz Z; Jaiswal V; Sarfraz M; Chérrez-Ojeda I
Clin Appl Thromb Hemost; 2021; 27():10760296211048815. PubMed ID: 34698582
[TBL] [Abstract][Full Text] [Related]
17. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
COVID-19 Forecasting Team
Lancet; 2022 Apr; 399(10334):1469-1488. PubMed ID: 35219376
[TBL] [Abstract][Full Text] [Related]
18. Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
Buhl C; Jacobsen R; Almarsdóttir AB; Abtahi S; Andersen A; Deligianni E; Dermiki-Gkana F; Kontogiorgis C; Oikonomou C; Kursite M; Poplavska E; Hegger I; van der Goot M; Sousa Ferreira PB; Ribeiro-Vaz I; Silva AM; Kos M; Lipovec NČ; van Vliet E; Alves TL
Vaccine; 2024 Jan; 42(3):556-563. PubMed ID: 38182460
[TBL] [Abstract][Full Text] [Related]
19. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
Milne GJ; Carrivick J; Whyatt D
BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
[TBL] [Abstract][Full Text] [Related]
20. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
